Effect of rifampicin on the pharmacokinetics of pioglitazone
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsThe transcriptional regulation of the human CYP2C genesTuberculosis and diabetes mellitus: convergence of two epidemics.Pharmacokinetic Drug Interaction Studies with Enzalutamide.No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteersEffects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.Thiazolidinedione safety.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity.Reduced prehepatic extraction of nicardipine in the presence of pioglitazone in rats.Exploring PTDH-P450BM3 Variants for the Synthesis of Drug Metabolites.Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.
P2860
Q24631021-A3FD5038-9C8C-410F-902A-E8AEB9B7CF4AQ33597311-9D2F31C0-5639-4C17-BC61-E92B53A55AE2Q34156234-0A037611-0079-42B4-9A23-A8820B3FE810Q36087515-EB232DD9-A85B-4397-8885-DE99B93C8C79Q36536042-1FEF7A0E-7DBA-4873-89A8-B5FDBBB5C522Q37141923-5857A0F6-86D2-4853-AF60-BB7FB89DE85EQ37469352-04311C0F-6102-4065-A141-F9ED19DC2C35Q37630384-BDF15C3D-CFB0-4FD0-8A95-4078DC7EB800Q38012205-CA3801AB-E950-42B5-A4AD-69F872476E29Q38028549-50AD19C5-2CCF-48AB-BE96-07077F809A28Q38057372-035B8AA4-F5AF-4DE7-9D27-248A7A000B70Q38059889-FC9C3E9F-AB1B-4440-ADE9-A6638CF07936Q38122640-F3CBCDB6-C495-423C-8F60-4BF74A6D91C0Q38130410-F7367DCD-D94A-4FB8-9834-672DBCBEA286Q38253580-338D2C7A-2C40-4AE2-8014-5A5C93831E55Q38684505-E59A3CA1-23EA-4DFE-A36C-E35791A49B07Q38780360-ED9F6A64-C3B5-4B03-88CC-E1A7D4BC1F55Q39418438-C9F39967-F510-46F4-8E3A-32E78BB2020CQ39509370-F27D9793-7457-47B7-8FCF-A2865271A0ABQ46351125-9F21B09B-A6AE-400C-B53D-2D119C011AE6Q49579327-94D93948-3983-4820-8F9F-EDE52FBA8D6AQ53086784-D128D7F3-F4F6-421D-BA28-E9019FFDA67B
P2860
Effect of rifampicin on the pharmacokinetics of pioglitazone
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Effect of rifampicin on the pharmacokinetics of pioglitazone
@ast
Effect of rifampicin on the pharmacokinetics of pioglitazone
@en
type
label
Effect of rifampicin on the pharmacokinetics of pioglitazone
@ast
Effect of rifampicin on the pharmacokinetics of pioglitazone
@en
prefLabel
Effect of rifampicin on the pharmacokinetics of pioglitazone
@ast
Effect of rifampicin on the pharmacokinetics of pioglitazone
@en
P2860
P50
P1476
Effect of rifampicin on the pharmacokinetics of pioglitazone
@en
P2093
Jouko Laitila
Tiina Jaakkola
P2860
P356
10.1111/J.1365-2125.2005.02515.X
P407
P577
2006-01-01T00:00:00Z